VALBIOTIS: 2021 Monetary Communication Calendar | Business enterprise & Finance

LA ROCHELLE, France–(Company WIRE)–Mar 11, 2021–

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / suitable for the PEA/SME), a Research & Enhancement firm fully commited to scientific innovation for stopping and combating metabolic ailments, these days provides its 2021 money interaction calendar.

– March, 17: Annual Report (just after current market closing)

– May perhaps, 27: General Meeting (conditions of participation to be specified afterwards)

– September, 30: 50 %-yr Report (right after market place closing)

VALBIOTIS is a Exploration & Advancement company dedicated to scientific innovation for protecting against and combating metabolic disorders in response to unmet professional medical wants.

VALBIOTIS has adopted an modern technique, aiming to revolutionize healthcare by creating a new course of nutritional well being answers made to lower the threat of significant metabolic health conditions, dependent on a multi-concentrate on strategy and created probable by the use of plant-based components.

Its merchandise are meant to be accredited to players in the wellbeing globe.

VALBIOTIS was established in La Rochelle in early 2014 and has formed quite a few partnerships with major academic facilities. The Company has set up a few sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the “BPI Excellence” network and received “Innovative Company“ standing awarded by BPI France. Valbiotis has also been awarded “Young Modern Company” position and has gained big fiscal assistance from the European Union for its study packages via the European Regional Progress Fund (ERDF). VALBIOTIS is a PEA-SME suitable business.

This push release incorporates ahead-searching statements about VALBIOTIS’ targets. VALBIOTIS considers that these projections are dependent on rational hypotheses and the info out there to the corporation at the current time. Even so, in no way does this constitute a ensure of foreseeable future general performance, and these projections may possibly be reconsidered dependent on alterations in financial situations and money marketplaces, as very well as a sure amount of threats and uncertainties, which include all those explained in the VALBIOTIS registration document, filed with the French Monetary Marketplaces Regulator (AMF) on 31 July 2020 (software amount R 20-018). This document is readily available on the Company’s web page ( ).

This press launch, as well as the details contained herein, does not represent an provide to market or subscribe to, or a solicitation to obtain or subscribe to, VALBIOTIS’ shares or securities in any nation.

Speak to: VALBIOTIS / Company Conversation

Carole Rocher / Marc Delaunay


Field Search phrase: Health and fitness Exercise & Nutrition Clinical TRIALS Analysis SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

Copyright Business Wire 2021.

PUB: 03/11/2021 11:40 AM/DISC: 03/11/2021 11:40 AM

Copyright Small business Wire 2021.